Esperion Therapeutics (ESPR) Set to Announce Earnings on Tuesday

Esperion Therapeutics (NASDAQ:ESPR) will be releasing its earnings data before the market opens on Tuesday, May 7th. Analysts expect Esperion Therapeutics to post earnings of ($0.17) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The firm had revenue of $32.25 million for the quarter, compared to analysts’ expectations of $26.84 million. During the same quarter in the previous year, the firm posted ($0.76) earnings per share. On average, analysts expect Esperion Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Esperion Therapeutics Stock Performance

ESPR opened at $2.08 on Friday. The business’s fifty day moving average is $2.34 and its two-hundred day moving average is $2.04. The company has a market cap of $393.95 million, a price-to-earnings ratio of -0.98 and a beta of 0.89. Esperion Therapeutics has a one year low of $0.70 and a one year high of $3.40.

Wall Street Analyst Weigh In

A number of research firms have commented on ESPR. Needham & Company LLC reiterated a “buy” rating and set a $8.00 target price on shares of Esperion Therapeutics in a research report on Wednesday, April 10th. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research note on Monday, March 25th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $9.33.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.